FI3977993T3 - 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä - Google Patents
6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä Download PDFInfo
- Publication number
- FI3977993T3 FI3977993T3 FIEP21203965.5T FI21203965T FI3977993T3 FI 3977993 T3 FI3977993 T3 FI 3977993T3 FI 21203965 T FI21203965 T FI 21203965T FI 3977993 T3 FI3977993 T3 FI 3977993T3
- Authority
- FI
- Finland
- Prior art keywords
- crystalline form
- medicine
- benzoxazole
- dichlorophenyl
- carboxy
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 6
- 239000007787 solid Substances 0.000 title claims 3
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 title claims 2
- 239000000126 substance Substances 0.000 claims 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047614P | 2014-09-08 | 2014-09-08 | |
| US201562203953P | 2015-08-12 | 2015-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3977993T3 true FI3977993T3 (fi) | 2024-03-25 |
Family
ID=54199901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21203965.5T FI3977993T3 (fi) | 2014-09-08 | 2015-08-31 | 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9770441B1 (enExample) |
| EP (3) | EP3191461B1 (enExample) |
| JP (5) | JP2016065042A (enExample) |
| KR (1) | KR102004059B1 (enExample) |
| CN (2) | CN115368313A (enExample) |
| AU (1) | AU2015313875B2 (enExample) |
| BR (1) | BR112017003421B1 (enExample) |
| CA (1) | CA2903194A1 (enExample) |
| CY (1) | CY1124843T1 (enExample) |
| DK (1) | DK3977993T3 (enExample) |
| ES (2) | ES2975633T3 (enExample) |
| FI (1) | FI3977993T3 (enExample) |
| HR (1) | HRP20211834T1 (enExample) |
| HU (2) | HUE065233T2 (enExample) |
| IL (1) | IL251037B1 (enExample) |
| LT (1) | LT3191461T (enExample) |
| MX (1) | MX374012B (enExample) |
| PL (2) | PL3977993T3 (enExample) |
| PT (2) | PT3191461T (enExample) |
| RS (1) | RS62634B1 (enExample) |
| SG (1) | SG11201700958YA (enExample) |
| SI (2) | SI3977993T1 (enExample) |
| TW (1) | TWI644902B (enExample) |
| WO (1) | WO2016038500A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| WO2020128816A2 (en) | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |
| PL3953339T3 (pl) * | 2019-04-11 | 2025-05-05 | Inke, S.A. | Proces otrzymania 1-deoksy-1-metyloamino-d-glucitolu 2-(3,5-dichlorofenylo)-6-benzoksazolokarboksylanu |
| US12391656B2 (en) | 2019-05-16 | 2025-08-19 | Assia Chemical Industries Ltd. | Solid state forms of Tafamidis and salts thereof |
| WO2021001858A1 (en) * | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| EP4059926A4 (en) | 2019-11-15 | 2022-12-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF |
| EP4077287B1 (en) * | 2019-12-20 | 2025-11-19 | Pfizer Ireland Pharmaceuticals Unlimited Company | Efficient process for making 6-carboxy benzoxazole derivatives |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| WO2021232619A1 (zh) * | 2020-05-19 | 2021-11-25 | 苏州科睿思制药有限公司 | 一种他发米帝司游离酸的晶型及其制备方法和用途 |
| US20230265059A1 (en) * | 2020-07-04 | 2023-08-24 | Nuray Chemicals Private Limited | Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof |
| WO2022084790A1 (en) * | 2020-10-19 | 2022-04-28 | Glenmark Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
| WO2022107166A1 (en) * | 2020-11-20 | 2022-05-27 | Natco Pharma Limited | Novel crystalline form of tafamidis and its process thereof |
| WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
| CN114907283B (zh) * | 2021-02-07 | 2025-01-28 | 南京正大天晴制药有限公司 | 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法 |
| CN114989106A (zh) * | 2021-02-09 | 2022-09-02 | 齐鲁制药有限公司 | 氯苯唑酸的新晶型及其制备方法 |
| EP4083027A1 (en) | 2021-04-26 | 2022-11-02 | Química Sintética, S.A. | A solid state form of tafamidis and a process for its preparation |
| WO2023020762A1 (en) | 2021-08-16 | 2023-02-23 | Synthon B.V. | Crystalline forms of tafamidis nicotinamide adduct |
| JP2024541422A (ja) | 2021-11-17 | 2024-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | タファミジスの固体状態の形態 |
| KR20250036933A (ko) | 2022-07-28 | 2025-03-14 | 화이자 인코포레이티드 | 타파미디스 약학 조성물 |
| WO2024084362A1 (en) * | 2022-10-17 | 2024-04-25 | Biophore India Pharmaceuticals Pvt. Ltd | A process for the preparation of crystalline form of tafamidis |
| US11878081B1 (en) | 2022-12-23 | 2024-01-23 | Tap Pharmaceuticals Ag | Pharmaceutical formulations of tafamidis |
| US11980685B1 (en) | 2022-12-23 | 2024-05-14 | Tap Pharmaceuticals, Ag | Liquid pharmaceutical formulations of tafamidis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DK1587821T6 (da) | 2002-12-19 | 2025-05-26 | Scripps Research Inst | Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning |
| CA2669849C (en) * | 2006-12-06 | 2012-01-31 | Pfizer Inc. | Crystalline forms of (3s)-3-[n-(n'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| SG2014013270A (en) * | 2011-09-16 | 2014-05-29 | Pfizer | Solid forms of a transthyretin dissociation inhibitor |
| US9499527B2 (en) * | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| US12391656B2 (en) | 2019-05-16 | 2025-08-19 | Assia Chemical Industries Ltd. | Solid state forms of Tafamidis and salts thereof |
| WO2021001858A1 (en) | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021152623A1 (en) | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
-
2015
- 2015-08-31 PT PT157712761T patent/PT3191461T/pt unknown
- 2015-08-31 PL PL21203965.5T patent/PL3977993T3/pl unknown
- 2015-08-31 BR BR112017003421-2A patent/BR112017003421B1/pt active IP Right Grant
- 2015-08-31 RS RS20211481A patent/RS62634B1/sr unknown
- 2015-08-31 WO PCT/IB2015/056597 patent/WO2016038500A1/en not_active Ceased
- 2015-08-31 PL PL15771276T patent/PL3191461T3/pl unknown
- 2015-08-31 EP EP15771276.1A patent/EP3191461B1/en active Active
- 2015-08-31 SI SI201532001T patent/SI3977993T1/sl unknown
- 2015-08-31 ES ES21203965T patent/ES2975633T3/es active Active
- 2015-08-31 HU HUE21203965A patent/HUE065233T2/hu unknown
- 2015-08-31 DK DK21203965.5T patent/DK3977993T3/da active
- 2015-08-31 US US15/509,343 patent/US9770441B1/en active Active
- 2015-08-31 FI FIEP21203965.5T patent/FI3977993T3/fi active
- 2015-08-31 SI SI201531753T patent/SI3191461T1/sl unknown
- 2015-08-31 EP EP24152053.5A patent/EP4349406B1/en active Active
- 2015-08-31 AU AU2015313875A patent/AU2015313875B2/en active Active
- 2015-08-31 KR KR1020177006011A patent/KR102004059B1/ko active Active
- 2015-08-31 ES ES15771276T patent/ES2901785T3/es active Active
- 2015-08-31 HU HUE15771276A patent/HUE056583T2/hu unknown
- 2015-08-31 EP EP21203965.5A patent/EP3977993B1/en active Active
- 2015-08-31 SG SG11201700958YA patent/SG11201700958YA/en unknown
- 2015-08-31 CN CN202211071641.7A patent/CN115368313A/zh active Pending
- 2015-08-31 MX MX2017002954A patent/MX374012B/es active IP Right Grant
- 2015-08-31 CN CN201580048168.2A patent/CN106715405A/zh active Pending
- 2015-08-31 LT LTEPPCT/IB2015/056597T patent/LT3191461T/lt unknown
- 2015-08-31 IL IL251037A patent/IL251037B1/en unknown
- 2015-08-31 PT PT212039655T patent/PT3977993T/pt unknown
- 2015-08-31 HR HRP20211834TT patent/HRP20211834T1/hr unknown
- 2015-09-02 JP JP2015172636A patent/JP2016065042A/ja not_active Withdrawn
- 2015-09-03 CA CA2903194A patent/CA2903194A1/en not_active Abandoned
- 2015-09-07 TW TW104129562A patent/TWI644902B/zh active
-
2019
- 2019-12-02 JP JP2019218244A patent/JP7357525B2/ja active Active
-
2021
- 2021-11-09 JP JP2021182622A patent/JP2022024014A/ja not_active Withdrawn
- 2021-12-16 CY CY20211101109T patent/CY1124843T1/el unknown
-
2023
- 2023-07-13 JP JP2023115087A patent/JP2023134645A/ja active Pending
-
2025
- 2025-04-15 JP JP2025066606A patent/JP2025108584A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3977993T3 (fi) | 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä | |
| AR101403A1 (es) | (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares | |
| PH12015502814A1 (en) | 4-membered ring carboxamides used as nematicides | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| IL246838B (en) | Compound (6-((4-carbamimidamidobenzol)oxy)-3,2-dihydro-1-benzofuran-3-yl)acetyl, a drug containing the compound and the compound for use as a drug | |
| MY182082A (en) | Biheteroaryl compounds and uses thereof | |
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| EP3143060B8 (en) | Catalysts for the synthesis of oxazolidinone compounds | |
| EP2867230A4 (en) | PROCESS FOR PREPARING 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLES | |
| Rossi et al. | Poincaré series of modules over compressed Gorenstein local rings | |
| EA201591530A1 (ru) | Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции | |
| EA201791219A1 (ru) | Антибактериальные композиции, имеющие широкий спектр активности | |
| EP3229238A4 (en) | System for the passive removal of heat from a water-cooled, water-moderated reactor via a steam generator | |
| MX2016001641A (es) | Ciclobutilcarboxamidas como nematicidas. | |
| WO2016016774A8 (en) | Crystalline forms of canagliflozin | |
| WO2017214423A8 (en) | Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof | |
| LT3212644T (lt) | 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-ilacetamido dariniai, kurie yra naudotini diabeto gydymui | |
| EP3865477A4 (en) | CARBON COMPOUND, CARBEN-METAL NANOPARTICLE COMPLEX AND MANUFACTURING PROCESS FOR IT | |
| GB201704384D0 (en) | N-((3,4,5-Trimethoxystyryl)aryl) cinnamamide compounds as potential anticancer agents and process for the preparation thereof | |
| WO2014174501A3 (en) | Use of metal scavengers for removal of ruthenium residues | |
| AR101778A1 (es) | Formas sólidas cristalinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol | |
| HK40038449A (en) | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders | |
| RU2016118748A (ru) | Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение | |
| TH144789B (th) | ของเล่น (รถตุ๊กตุ๊ก) | |
| CN302040939S (zh) | 车位锁(a型) |